COHBAR INC. overview
COHBAR INC. > News
GlobeNewsWire published a news.
Morphogenesis, Inc. and CohBar, Inc. Announce Positive Results from Phase 1b Trial of IFx-Hu2.0, a Novel Personalized Cancer Vaccine, in Checkpoint Inhibitor Resistant Advanced Merkel Cell Carcinoma (MCC) and Cutaneous Squamous Cell Carcinoma (cSCC)
•
•
GlobeNewsWire •
Stocks •
More COHBAR INC. news...
Thank you